ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last581 to 600 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Omega-3 vs Placebo Omega-3: Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)166 of 7,740

135 of 7,740

0.4 points

-0.0 to 0.8

15,480NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Coronavirus Disease 2019 (COVID-19)200 of 7,762

440 of 7,696

-3.1 points

-3.8 to -2.5

15,458NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

GSK1437173A Group vs Placebo Group: Number of Subjects With Fatal SAEs208 of 7,695

221 of 7,710

-0.2 points

-0.7 to 0.4

15,405NCT01165177

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

GSK1437173A Group vs Placebo Group: deaths from any cause11 of 7,695

15 of 7,710

-0.1 points

-0.2 to 0.1

15,405NCT01165177

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

GSK1437173A Group vs Placebo Group: Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine43 of 7,695

25 of 7,710

0.2 points

0.0 to 0.5

15,405NCT01165177

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

GSK1437173A Group vs Placebo Group: serious adverse events727 of 7,695

731 of 7,710

-0.0 points

-1.0 to 0.9

15,405NCT01165177

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of RT-PCR-Confirmed RSV Mediated LRTD During the Second Year16 of 10,031

29 of 5,011

-0.4 points

-0.7 to -0.2

15,042NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV Mediated ARI During the Second Year39 of 10,031

44 of 5,011

-0.5 points

-0.8 to -0.2

15,042NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

CSL's IVV vs Placebo: serious adverse events100 of 10,015

44 of 5,005

0.1 points

-0.2 to 0.4

15,020NCT00562484

A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

APPROACHES ACP Specialist Program vs Control: Hospice Enrollment1,095 of 7,474

1,181 of 7,358

-1.4 points

-2.6 to -0.2

14,832NCT03323502

Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support

APPROACHES ACP Specialist Program vs Control: deaths from any cause2,005 of 7,474

1,980 of 7,358

-0.1 points

-1.5 to 1.3

14,832NCT03323502

Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support

Asundexian vs Apixaban: Number of Participants With All-cause Mortality60 of 7,415

71 of 7,395

-0.2 points

-0.5 to 0.2

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Cardiovascular (CV) Death48 of 7,415

44 of 7,395

0.1 points

-0.2 to 0.3

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of Ischemic Stroke or Systemic Embolism96 of 7,415

22 of 7,395

1.0 points

0.7 to 1.3

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Ischemic Stroke85 of 7,415

21 of 7,395

0.9 points

0.6 to 1.1

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)155 of 7,415

77 of 7,395

1.0 points

0.7 to 1.5

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of Stroke or Systemic Embolism98 of 7,415

26 of 7,395

1.0 points

0.7 to 1.3

14,810NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal MI228 of 7,434

213 of 7,330

0.2 points

-0.4 to 0.7

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal Stroke102 of 7,434

92 of 7,330

0.1 points

-0.3 to 0.5

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: Number of Participants Experiencing All-cause Death315 of 7,434

357 of 7,330

-0.6 points

-1.3 to 0.0

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=30

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00135226-a516410a",
        "title": "Omega-3 vs Placebo Omega-3: Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)",
        "summary": "166 of 7740 against 135 of 7740; risk difference 0.4 points, 95% interval -0.0 to 0.8; NCT00135226, ASCEND: A Study of Cardiovascular Events iN Diabetes",
        "record": "/library/comparisons/NCT00135226-a516410a",
        "nct_id": "NCT00135226",
        "kind": "outcome",
        "participants": 15480,
        "risk_difference": {
          "value": 0.004005167958656332,
          "lower": -0.00035421639074811884,
          "upper": 0.008395516238125424
        },
        "group_1": "166 of 7,740",
        "group_2": "135 of 7,740",
        "difference": "0.4 points",
        "interval": "-0.0 to 0.8",
        "trial_title": "ASCEND: A Study of Cardiovascular Events iN Diabetes"
      },
      {
        "id": "NCT05012943-38dadd9d",
        "title": "ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Coronavirus Disease 2019 (COVID-19)",
        "summary": "200 of 7762 against 440 of 7696; risk difference -3.1 points, 95% interval -3.8 to -2.5; NCT05012943, The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)",
        "record": "/library/comparisons/NCT05012943-38dadd9d",
        "nct_id": "NCT05012943",
        "kind": "outcome",
        "participants": 15458,
        "risk_difference": {
          "value": -0.031406002160962225,
          "lower": -0.03774273540687387,
          "upper": -0.025170527975553497
        },
        "group_1": "200 of 7,762",
        "group_2": "440 of 7,696",
        "difference": "-3.1 points",
        "interval": "-3.8 to -2.5",
        "trial_title": "The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=31",
  "request_id": "YsTUvYbPrEGKPogA"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?